AnaptysBio Inc(ANAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 7.49 | EPS (ttm) | 6.45 | Insider Own | 6.62% | Shs Outstand | 29.7M | Perf Week | -0.92% |
| Market Cap | 1.44B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.25% | Shs Float | 27.9M | Perf Month | -0.72% |
| Enterprise Value | 1.55B | PEG | - | EPS next Q | 0.85 | Inst Own | 102.98% | Short Float | 19.31% | Perf Quarter | -10.03% |
| Income | 0.20B | P/S | 6.07 | EPS this Y | - | Inst Trans | 4.79% | Short Ratio | 10.83 | Perf Half Y | -27.68% |
| Sales | 0.24B | P/B | 135.6 | EPS next 5Y | - | ROA | 70.78% | Short Interest | 5.39M | Perf YTD | 49.4% |
| Book/sh | 0.36 | P/C | 8.79 | EPS past 3/5Y | 53.48% 8.82% | ROE | -114.55% | 52W High | -33.28% ($72.36) | Perf Year | 98.6% |
| Cash/sh | 5.49 | P/FCF | 79.87 | Sales past 3/5Y | 183.58% 25.62% | ROIC | 70.4% | 52W Low | 139.28% ($20.18) | Perf 3Y | 339.24% |
| Dividend Est. | - | EV/EBITDA | 11.38 | EPS Y/Y TTM | 249.01% | Gross Margin | 96.78% | Volatility(W/M) | 3.51% 4.58% | Perf 5Y | 120.15% |
| Dividend TTM | - | EV/Sales | 6.52 | Sales Y/Y TTM | 92.92% | Oper. Margin | 56.36% | ATR (14) | 2.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.61 | EPS Q/Q | 561.29% | Profit Margin | 82.37% | RSI (14) | 46.75 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.61 | Sales Q/Q | 23.47% | SMA20 | 1.24% ($47.69) | Beta | 0.85 | Target Price | $79.71 |
| Payout | - | Debt/Eq | 25.46 | Earnings | 2026/9/21 | SMA50 | -6.72% ($51.76) | Rel Volume | 0.59 | Prev Close | $48.64 |
| Employees | 104 | LT Debt/Eq | 25.25 | EPS/Sales Surpr. | - | SMA200 | -4.21% ($50.4) | Avg Volume(3M) | 0.50M | Price | $48.28 |
| IPO | 2017/1/26 | Option/Short | Yes/Yes | Trades | 4118 | Volume | 293,633 | Change | -0.74% |
🧬 This is a US-based clinical-stage biotech company developing antibody therapeutics for immune and inflammatory diseases. It develops candidates that target autoimmune and inflammatory diseases using its immune-modulating antibody technology and operates a model that combines royalties from partnerships with its own pipeline. The company has established itself as a differentiated immune and inflammatory biotech with its immune-modulating antibody approach.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
ANAB makes money exceptionally well
Of every $100 in sales, $56.36 is kept as operating profit.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $749. Peers typically go for $749.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +120.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 103.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #131 of 597 in the industry
Based on market cap of $1B.
LYCA#129 Lycia Therapeutics Inc $1B PER - 
TYRA#130 Tyra Biosciences Inc $1B PER - ANAB#131 AnaptysBio Inc $1B PER 7.5 
GHRS#132 GH Research PLC $1B PER - 
KRSA#133 Korsana Biosciences Inc $1B PER - 
FAQ
What kind of company is ANAB?
ANAB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANAB?
The market cap of ANAB is approximately $1.4B, ranking 2,320 within its sector.
What is the P/E ratio of ANAB?
ANAB has a P/E ratio of approximately 7.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ANAB?
ANAB has recorded a 52-week high of $72.36 and a low of $20.18.
